The bottom line here is how or whether our toxicological studies relate to ourselves, to human neoplasia-but the latter is, in important ways, imperfectly defined by the best that can so far be arranged using morphological and epidemiologic methods. There are at least three basic questons: 1) with what precision can the histopathologist define and diagnose cancer in humanshence emphasis here upon human cancer models, 2) to what extents can difficulties be resolved using animal models, where some similar difficulties are met, and 3) to what extents can epidemiology resolve these difficulties. Not all these problems can be resolved, and the investigator is leftawith a residue of questions for which no answers are presently available. Some of these are exemplified or precipitated by inconclusive or mistaken diagnoses.
INTRODUCTION
perhaps the most dangerous fallacy is to ascribe complete confidence to histopathobiopsy-or necropsy-. The harassed histoto leap to immediate histopathological diagakin to amateur bird watching than to serious science. When the diagnostic process is bro-\,,hen is reviewed in turn, there, are often no absolute answers. No (3, 9) or wrong-the clue to doubt is sometimes the use of the term "borderline". But all scientists must be capable of recognizing the limits of their methods, their experience and their intelligence, admitting to doubt and the possibilities of error when such arise. Ninety-five percent confidence limits are laudable enough in statistics but, in this instance this seemingly innocent 5% figure is not a statistic, it is a guess-and educated or otherwise, cold comfort to the five percent or whatever lies beyond the limit (3). It could be you or your experiment.
The clinician turns to follow-up studies of patients, the toxicologist to his experimental animals where morphologic problems are much the same, but confounding factors of treatment are reduced and serial observations are possible. When investigators turn to epidemiology, they are to be confronted by other pitfalls, eg. human situations that do not fully correspond to experimental models, as in the current formaldehyde controversy, where experimental animals have been subject under controlled conditions to episodic exposure, human occupational (2, 6) exposure is episodic, and control studies in humans are bedeviled by the ubiquity of formaldehyde (6)-and the investigator may be confronted by confounding factors relating more to the alarm, despondency and financial distress of the human victim than to clear cut organic disease (4, 6). In a recent communication on this subject, relatively less reliable data, ie. the use of cancer death data rather than cancer treatment data (8), were obtained from reliable agencies that can and willingly do supply both. Obviously, epidemiological studies which are supported by resources akin to those of the Normandy campaign are likely to turn up much valuable information yet, again to turn to the formaldehyde example, the writer is unaware of approaches to cancer registry agencies with respect to treatment of cancer in formaldehyde exposed individuals (14); here much of the work can be done by the post office. Mortality figures, particularly those based on certification of death, are likely to be misleading, since data relating to occupation, clinical history and prior treatment are so often incomplete.
It is held that epidemiological studies in humans often do not include reviews, critiques and interpretation of data from animal models (5). When such correlation is ,attempted, inconsistencies may appear, eg. the evident carcinogenicity of formaldehyde in rodents and the lack of a corresponding response in humans subject to the episodic occupational exposures just now related. Thus the important question of continuous human response to low level exposure to formaldehyde, so crucial in the current UFFI controversy, remains so far unanswered. Conversely, the apparently positive responses of the human model to methyl-xanthine exposure has not been matched in experimental animals. For progestogens, the commonly used dog is a misleading model while, for estrogens, various animal models appear to provide acceptable parallels to the human response.
An epidemiologic model may be simplicity itself. Nonoxynol9 (N-9) spermatocide in dosages 10-20 times the clinically employed levels evokes violent vaginitis and endometritis in rodents, and lesser responses in lower genital tracts of primates (16, 18, 19) . To investigate human responses one has only to "piggy-back" an inquiry onto the monitoring of human females by examination of vaginal exfoliates. Some such monitoring must be routine for any contraceptive method, but so far as the authors are aware, specific attention to the possibility of N-9 induced vaginitis and cervicitis is not yet a part of such routines.
A final limitation has been aptly described by Stafford Beer in the monograph entitled "Designing freedom", the 1973 Massey lectures of the Canadian Broadcasting Corporation (1): "The first thing we have to face up to is quite a tough proposition for people reared in our culture. It is that whatever we humans can do is mediated by our brains, and those brains are finite. We have in the cranium a slightly alkaline three-pound electrochemical computer running on glucose at about 25 watts. This computer contains some ten thousand million (that's ten to the ten) logical elements called neurons, operating on a basic scanning rhythm of ten cycles per second. Then this is a high-variety dynamic system all right; but it really is finite. It fol-169 lows from Ashby's Law that we can recognize patterns up to a certain limit, and not beyond. Thus if something is going on that involves a higher variety than the brain commands, we shall not recognize what it is. This is the old constraint of requisite variety again.
There are practical consequences to this. For instance, I am sure that the reason why we are making such a hash of the problems of global ecology is that we cannot understand them. I don't just mean that they are awfully difficult, so that understanding will take a lot of research. I mean that we can not understand at all, ever. Very likely this goes for many problems of government too, especially world government. It may even be true at the level of recursion where a corporation is managed. May I recall that the level of recursion is simply the focus of attention at which we contemplate any viable system, and that one level is contained within the next. So here is an unpleasing thought: maybe it is also true at our personal level of recursion. Perhaps we cannot actually understand our 'own lives, our own environment, any longer. Now with or without full understanding, with or without the requisite variety to detect vital patterns, we have to cope somehow at all these levels. Of course we do it by making mental models. We simplify, so that the system we are considering will map onto our own brains. But that can be done only by attenuating variety, and we have no guarantee that we are not throwing the wrong information away. It is fairly evident that we shall become accustomed to discarding information in set ways, and to eliminating inputs that do not seem to fit very well the methods we have developed. I think this must mean that what we all refer to as "reality" is a version of the universe that is very much cut off at the knees. To be rude about it, you could say that our humanity exists in sharing a delusion about the way things are".
Surely there is nothing new in this. Scientific evidence is intrinsically focused upon questions that are specific and rigorously specified; the scientist does not pretend to provide sweeping, exact and final panoramas of an entire universe. Beer's idea, already cited (I), that each investigator represents an individual set of mental models, expresses a safeguard against facile and bogus agreement, promoting rigor in selecting priorities and in designing procedures. Accordingly, we can follow a view that present diagnostic constraints are mainly those of methods, with standard unassisted light microscopy having been nearly or partly milked dry (17) . Now we do have the advantages of a common terminology in SNOVET and SNOMED, with their computer codgs. The pharmacological pathologist has fhe guidance of Irey's postulates for identifying adverse drug reactions and measuring various of their effects (7). Communicating in consultation using microscope, TV camera, monitor and satellite means that any of us with a problem can communicate with any consultant we want-once the existing hardware is in place. This has been done on an Ottawa-Vancouver link by Canadian Tumor Reference Centre Pathologists (10) (Figure 1) .
From selections of data from rapidly advancing methodologies from many disciplines may soon or sometime come the concatenations of evidence leading from reliable recognition of the initiated cell to more reliable recognition of autonomous proliferation, with reasonable expectations that time spans between initiation and autonomy would more often allow for truly early, specific clinical diagnosis of cancer and timely specific therapy (3, 12).
Autonomy may be late in carcinogenesis but, at present, reliable recognition of this state often remains elusive while signals from the initiated cell are being jammed with false messages precluding widely applicable diagnostic use in the human patient (12). Nevertheless, awareness of the chances for error and frequent consultation help ensure that mistaken diagnoses are few, and the future holds the promise of more practical approaches to cancer diagnosis using specific biochemical, hematologic, molecular, genetic or immunological markers and simplified, automated morphometric methods. A wary optimism may be justified.
As for the theme of this talk, the pathologist can indeed expect in the near future to make new contributions to interfaces with epidemiology, and not only in cancer studies. Is it necessary to wait for the "new" pathology? One model for collaboration in such interfaces is exemplified by the expert panel on methylxanthine consumption and fibrocystic breast disease, in which university and teaching hospital investigators in epidemiology and pathology, radiology and surgery as well, met together in workshop milieux, in collaboration to compose their conjoint findings (13) . No new-fangled methodology or data were needed. With regard to some carcinogenetic familial syndromes, epidemiological and pathological data already available have for years been quite sufficient for preventive measures. Is it necessary for fellow citizens to be destined to fates such as those of eg. familial polyposis of colon when societal and economic pressures are already limiting conception of the genetically unimpaired? Obviously such familial problems are few, which is all the more reason to urge that, in the excitement of getting on with the new, we do not neglect to get the most out of what action can achieve now.
Even surveys of lowly "routine" surgical pathology specimens in humans can, in the hands of the epidemiologist-cum-pathologist, lead to findings unexpected except, perhaps, in afterthought, eg. the 82.66% predominance of females among 496 of 34,037 surgical patients having adverse drug reactions and, within the group of afflicted females, the predominance of estrogens causing endometrial hyperplasia in 132 of these patients and, in another 89, abnormal endometrial maturation. In yet another 19 estrogen-treated patients with endometrial hyperplasia, carcinoma of endometrium was also found (11).
